The role of Epstein-Barr virus in lymphoid malignancies

Critical Reviews in Oncology/Hematology

Volumn 26, Issue 1, 1997, Pages 25-41

  Su, Ih Jen ^a   Chen, Jen Yang ^b  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BURKITT LYMPHOMA; CANCER RISK; EPSTEIN BARR VIRUS; HUMAN; LYMPHOMA; REVIEW; VIRUS CARCINOGENESIS; VIRUS CELL INTERACTION;

EID: 0030795263     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(97)00008-5     Document Type: Article

References (148)

1. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphocytes from Burkitt's lymphoma. Lancet 1964;1:702-3.
2. Epstein MA, Achong BA, editors. Epstein-Barr Virus: Recent Advances. New York: John Wiley, 1986;1:11.
3. Diehl V, Henle G, Henle W, Kohu G. Demonstration of a herpes group virus in cultures of peripheral leukocytes from patients with infectious mononuelcosis. J Virol 1968;2:663-9.
4. zur Hausen H, Schulte-Holthausen H, Klein G, Henle W, Henle G, Clifford P, Santesson L. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 1970;228:1056-8.
5. List AF, Greco FA, Vogler LB. Lymphoproliferative diseases in immunocompromised hosts: the role of Epstein-Barr virus. J Clin Oncol 1987;5:1673-89.
6. Hanto DW, Gajl-Peczalska KJ, Frizzera G, et al. Epstein-Barr virus induced polyclonal and monoclonal B-cell lymphoproliferative disease occurring after renal transplantation: Clinical, pathologic and urologic findings and implications for therapy. Ann Surg 1983;198:356-69.
7. Doll DC, List AF. Burkitt's lymphoma in a homosexual. Lancet 1982;1:1026-7.
8. Ziegler JL, Miner RC, Rosenbaum E, et al. Outbreak of Burkitt's-like lymphoma in homosexual men. Lancet 1982;2:631-3.
9. Kieff, E., Leibowitz, D., The Epstein-Barr virus and its replication. In: Fields BN, Knipe DM, editors. Fundamental Virology. New York: Raven Press, 1991;897.
10. Miller, G. Epstein-Barr virus: biology, pathogenesis and medical aspects. In: Fields BN, Knipe DM. editors. Fundamental Virology. New York NY: Raven Press, 1991;1921.
11. Weiss LM, Movahed LA, Warnke RA, Sklar J. Detection of Epstein-Barr viral genomes in Reed-sternberg cells of Hodgkin's disease. N Engl J Med 1989;320:502-6.
12. Brocksmith KD, Angel CA, Pringle JH, Lauder I. Epstein-Barr viral DNA in Hodgkin's disease: Amplification and detection using the polymerase chain reaction. J Pathol 1991;165:11-5.
13. Wright CF, Reid AH, Tsai MM, et al. Detection of Epstein-Barr virous by the polymerase chain reaction. Am J Pathol 1991;139:393-8.
14. Brousset P, Chittal KS, Schlaifer D, et al. Detection of Epstein-Barr virus messenger mRNA in Reed-Sternberg cells of Hodgkin's Disease by in situ hybridisation with biotinylated probes on specially processed modified acetone methyl benzoate xylene ModAMeX sections. Blood 1991;77:1781-6.
15. Murray G, Young LS, Rowe M, Crocker J. Immunohistochemical demonstration of the Epstein-Barr virus-encoded latent membrane protein inparrafin sections of Hodgkin's Disease. J Pathol 1992;166:1-5.
16. Jones JF, Shurin S, Abramowsky C, et al. T-cell lymphomas containing Epstein Barr virus DNA in patients with chronic Epstein-Barr virus infections. N Engl J Med 1988;318:733-6.
17. Harabuchi Y, Yamanaka N, Kataura A, et al. Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet 1990;335:128-30.
18. Su IJ, Hsieh HC, Lin KH, et al. Aggressive peripheral T-cell lymphomas containing Epstein-Barr viral DNA: a clinicopathological and molecular analysis. Blood 1991;68:1954-63.
19. Pallesen G, Hamilton-Dutoit SJ, Zhou X. The association of Epstein-Barr virus (EBV) with T cell lymphoproliferations and Hodgkin's disease: two new developments in the EBV field. Adv Cancer Res 1993;62:179-239.
20. Zhou XG, Hamilton-Dutoit SJ, Yan QG, Pallesen G. High frequency of Epstein-Barr virus in Chinese peripheral T-cell lymphoma. Histopathology 1994;24:115-22.
21. Huen DS, Henderson SA, Croom-Carter D, Rowe M. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kB and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 1995;10:549-60.
22. Knecht H, Bachmann E, Brousset P, et al. Deletions within the LMP1 oncogene of Epstein-Barr Virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma. Blood 1993;82:2937-41.
23. Knecht H, Bachmann E, Brousset P, et al. Mutational hot spots within the carboxy terminal region of the LMP1 oncogene of Epstein-Barr virus are frequent in lymphoproliferative disorders. Oncogene 1995;10:523-8.
24. Knecht H, Raphael M, Mcquain C, et al. Deletion variants within the NF-kB activation domain of the LMP1 oncogene prevail in acquired immunodeficiency syndrome-related large cell lymphomas and human immunodeficiency virus-negative atypical lymphoproliferations. Blood 1996;87:876-81.
25. Kingma DW, Weiss WB, Jaffe ES, et al. Epstein-Bar virus latent membrane protein-1 oncogene deletions: Correlations with malignancy in Epstein-Barr virus-associated lymhphoproliferative disorders and malignant lymphomas. Blood 1996;88:242-51.
26. Fingeroth JD, Weiss JJ, Tedder TF, et al. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci USA 1984;81:4510-4.
27. Wilson BS, Platt JL, Kay NE. Monoclonal antibodies to the 140,000 mol wt glycoprotein of B lymphocyte membrane (CR2 receptor) initiates proliferation of B cells in vitro. Blood 1985;66:824-9.
28. Nemerow GR, Wolfert R, McNaughton ME, et al. Identification and characterization of the EBV receptor on human B lymphocytes and its relationship to the C3d receptor (CR2). J Virol 1985;55:347.
29. Fingeroth JD, Clabby ML, Strominger JD. Characterization of a T-lymphocyte Epstein-Barr virus C3d receptor (CD21). J Virol 1988;0:1442-7.
30. Watry D, Hedrick JA, Siervo S, et al. Infection of human thymocytes by Epstein-Barr virus. J Exp Med 1991;173:971-80.
31. Thorley-Lawson DA, Schooley RT, Bhan AK, et al. Epstein-Barr virus superinduces a new human B cell differentiation antigen (BLAST-1) expressed on transformed lymphoblasts. Cell 1982;30:415-25.
32. Thorley-Lawson DA, Mann KP. Early events in Epstein-Barr virus infection provide a model for B cell activation. J Exp Med 1985;162:45-59.
33. Weiss LM, Jaffe ES, Liu XF, Chen YY, Shibata D, Medeiros LJ. Detection and localisation of Epstein-Barr viral genomes in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphomas. Blood 1992;79:1789-95.
34. Baer R, Bankier AT, Biggin MD, et al. DNA sequence and expression of the B95- Eptein-Barr virus genome. Nature 1984;310:207-11.
35. Raab-Traub N, Flynn K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 1986;47:883-9.
36. Rowe M, Lear AL, Croom-Carter DD, Davies AH, Rickinson AB. Three pathways of Epstein-Barr virus gene activation from EBNA-1 positive latency in B lymphocytes. J Virol 1992;66:122-31.
37. Murray RJ, Kurilla MG, Brooks JM, et al. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): Implications for the immune control of EBV-positive malignancies. J Exp Med 1992;176:157-68.
38. Khan G, Coates PJ, Kangro HO, Slavin G. Epstein-Barr virus (EBV) encoded small RNAs: Targets for detection by in situ hybridisation with oligonucleotide probes. J Clin Pathol 1992;45:616-20.
39. Gregory CD, Murray RJ, Edwards CF, Rickinson AB. Down-regulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumour cell escape from virus-specific T cell surveillance. J Exp Med 1988;167:1811-24.
40. Levitskaya J, Coram M, Levitsky V, et al., Inhibition of antigen processing by the internal repeat region of the Epstein-Barr rvirus nuclear antigen-1. Nature 1996;375:685-8.
41. Yates JL, Warren N, Reisman D, Sugden B. A cis-acting element from the Epstein-Barr virus genome that permits stable replication of recombinant plasmids in latently infected cells. Proc Natl Acad Sci USA 1984;81:3806-18.
42. Wang F, Gregory C, Sample C, et al. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol 1990;64:2309-18.
43. Cohen JI, Wang F, Mannick J, Kieff E. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci USA 1989;86:9558-62.
44. Wang D, Leibowitz D, Kieff E. An EBV membrane protein expressed in immortalised lymphocytes transforms established rodent cells. Cell 1985;43:831-40.
45. Peng M, Lundgren E. Transient expression of the Epstein-Barr virus LMP-1 gene in human primary B cells induces cellular activation and DNA synthesis. Oncogene 1992;7:1775-82.
46. Birkenbach M, Liebowitz D, Wang F, et al. Epstein-Barr virus latent membrane protein increases vimentin expression in human B-cell lines. J Virol 1989;63:4079-84.
47. Walter J, Schirrmacher V, Mosier D. Induction of CD44 expression by the Epstein-Barr virus latent membrane protein LMP1 is associated with lymphoma dissemination. Int J Cancer 1995;61:363-9.
48. Gregory CD, Dive C, Herderson S, et al. Activation of Epstein-Barr virus latent genes protects human B-cells from death by apoptosis. Nature 1991;349:612-4.
49. Henderson S, Rowe M, Gregory C, et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 1991;65:1107-15.
50. Okan I, Wang Y, Chen F, et al. The EBV -encoded LMP1 protein inhibits p53 triggered apoptosis but not growth arrest. Oncogene 1995;11:1027-31.
51. Dawson CW, Rickinson AB, Young LS. The latent membrane protein (LMP-1) inhibits epithelial differentiation. Nature 1990;344:377-80.
52. Mosialos G, Birkenbach M, Yalamanchili R, et al. The Epstein-Barr virus transforming protein LMP engages in singnaling proteins for the tumor necrosis factor receptor family. Cell 1995;80:389-99.
53. Huen DS, Henderson SA, Croom-Carter D, Rowe M. The Epstein-Barr virus latent membrane protein-1(LMP1) mediates activation of NF-kB and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 1995;10:549-60.
54. Mitchell T, Sugden B. Stimulation of NF-kB-Mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr virus. J Virol 1995;75:2968-76.
55. Herrero JA, Mathew P, Paya CV. LMP-1 activates NF-kB by targeting the inhibitory molecule IkBa. J Virol 1995;4:2168-74.
56. Fruehling S, Lee SK, Herrold R, et al. Identification of latent membrane protein 2A (LMP2A) domains essential for the LMP2A dominant-negative effect on B-Lymphocyte surface immunoglobulin signal transduction. J Virol 1996;9:6216-26.
57. Robertson ES, Lin J, Kieff E. The Amino-Terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B, and 3C interact with RBPJk. J Virol. 1996;5:3068-74.
58. Klein G. Epstein-Barr virus strategy in normal and neoplastic B cells. Cell 1994;77:791-3.
59. Chen F, Zou JZ, Renzo LD, et al. A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt's lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP-1. J Virol 1995;69:3752-8.
60. Chen CL, Sadler RH, Walling DM, Su IJ, et al. Epstein-Barr virus (EBV) gene expression in jEBV expression in EBV-positive peripheral T-cell lymphomas. J Virol 1993;67:6303-8.
61. Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young, LS., Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's Disease. Lancet 1991;1:320-2.
62. Paterson JRL, Kelleher C, Amankonah TD, et al., Model of Epstein-Barr virus infection of human thymocytes: expression of viral genome and impact on cellular receptor expression in the T-lymphoblastic cell line. HPB-ALL. Blood 1995;85:456-64.
63. Suzushima H, Asou N, Fujimoto T, et al. Lack of the expression of EBNA-2 and LMP-1 in T-cell neoplasms possessing Epstein-Barr virus. Blood 1995;85:480-6.
64. Chang YS, Su IJ, Chung PJ, et al. Detection of an Epstein-Barr virus variant in T cell lymphoma tissues identical to the distinct strain observed in nasopharyngeal carcinoma in the Taiwanese population. Int J Cancer 1995;62:673-7.
65. Wu SJ, Lay JD, Chen CL, et al. Genomic analysis of Epstein-Barr virus in nasal and peripheral T-cell lymphoma: A comparison with nasopharyngeal carcinoma in an endemic area. J Med Virol 1996;50:314-21.
66. Longnecker R, Miller CL, Tomkinson B, et al. Deletion of DNA encoding the first five transmembrane domains of Epstein-Barr virus latent membrane proteins 2A and 2B. J Virol 1993;8:5068-74.
67. Khanna R, Burrows SR, Moss DJ, Silins SL. Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: Implications for cytotoxic T-lymphocyte control of EBV-associated malignancies. J Virol 1996;8:5357-62.
68. Sinclair SJ, Brimmell M, Farrell PJ. Reciprocal antagonism of steroid horomones and BZLF1 in switch between Epstein-Barr virus latent and productive cycle gene expression. J Virol 1992;1:70-7.
69. Kerr BM, Lear AL, Rowe M, et al. Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: Cell phenotype dependence of virus promoter usage. Virology 1992;187:189-201.
70. Henle G, Henle W. Observations on childhood infections with the Epstein-Barr virus. J Infect Dis 1970;121:303-9.
71. Purtilo DT, Cassel C, Yang JPS, et al. X-linked recessive progressive combined variable immunodeficiency (Duncan's disease). Lancet 1975;1:935-41.
72. Purtilo DT, Sakamoto K, Barnabei V, et al. Epstein-Barr virus-induced diseases in boys with the X-linked lymphoproliferative syndrome (XLP). Am J Med 1982;73:49-56.
73. Chen RL, Su IJ, Lin KH, et al. Fulminant childhood hemophagocytic syndrome mimicking histiocytic medullary reticulosis: an atypical form of EBV infection. Am J Clin Pathol 1991;96:171-6.
74. Su IJ, Wang C, Cheng A. Hemophagocytic syndrome in Epstein-Barr virus-associated T-lymphoproliferative disorders: disease spectrum, pathogenesis, and management. Leukemia Lymph 1995;18:401-6.
75. Su IJ, Chen RL, Lin DT, Lin KS, Chen CC. Epstein-Barr virus (EBV) infects lymphocytes in childhood EBV-asspciated hemophagocytic syndrome in Taiwan. Am J Pathol 1994;144:1219-25.
76. Kawaguchi H, Miyashita T, Herbst H, et al. Epstein-Barr virus-infected T lymphocytes in Epstein-Barr virus-associated hemophagocytic syndrome. J Clin Invest 1993;92:1444-50.
77. Lombardi L, Newcomb EW, Dalla-Favera R. Pathogenesis of Burkitt lymphoma: expression of an activated c-myc oncogene causes the tumorigenic conversion of EBV-infected human B lymphoblasts. Cell 1987;49:161-70.
78. Hotchin MA, Allday MJ, Crawford DH. Deregulated c-myc expression in Epstein-Barr immortalised B-cells induces altered growth properties and surface phenotype but not tumorigenicity. Int J Cancer 1990;45:566-71.
79. Oudejans JJ, van den Brule AJC, Jiwa NM, et al. BHRF1, the Epstein-Barr virus (EBV) homologue of the BCL-2 proto-oncogene, is transcribed in EBV-associated B-cell lymphomas and in reactive lymphocytes. Blood 1995;86:1893-902.
80. Dawson CW, Eliopoulos AG, Dawson J, Young LS. BHRF1, a viral homologue of the Bcl-2 oncogene, distrubs epithelial cell differentiation. Oncogene 1995;9:69-77.
81. Klein G. Lymphoma development in mice and humans: Diversity of initiation is followed by convergent cytogenetic evolution. Proc Natl Acad Sci USA 1979;76:2442-6.
82. Klein G, Klein E. Evolution of tumors and the impact of molecular oncology. Nature 1985;315:190-5.
83. Hanto DW, Frizzera G, Gajl-Peczalska J, et al. The Epstein-Barr virus (EBV) in the pathogenesis of posttransplant lymphoma. Transplant Proc 1981;16:756-60.
84. Starzl TE, Porter KA, Iwatsuki S, et al. Reversibility of lymphoma and lymphoproliferative lesions developing under cyclosporine-steroid therapy. Lancet 1984;1:583-7.
85. Calne RY, Rolles KM, White DJG, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreas, and 2 livers. Lancet 1979;2:1033-6.
86. Rowe M, Young LS, Crocker J, et al. Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: Implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med 1991;173:147-58.
87. Purtilo DT, Strobach RS, Okano M, Davis JR. Biology of disease: Epstein-Barr virus associated lymphoproliferative disorders. Lab Invest 1992;67:5-23.
88. Polack A, Hortnagel K, Pajic A, et al. C-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells indepecdent of EBV nuclear antigen 2 and latent membrane protein 1. Proc Natl Acad Sci USA 1996;93:10411-6.
89. Lindahl T, Klein G, Reedman BM, et al., Relationship between Epstein-Barr virus (EBV) DNA and the EBV determined nuclear antigen (EBNA) in Burkitt's lymphoma biopsies and other lymphoproliferative malignancies. Int J Cancer 1974;1:764-72.
90. Shapiro RS, McClain K, Frizzera G, et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988;71:1234-43.
91. Hanto DW, Frizzera F, Purtilo DT, et al. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res 1981;41:4253-61.
92. Crawford DH, Thomas JA, Janossy G, et al. Epstein-Barr virus nuclear antigen positive lymphoma after cyclosporing A treatment in patients with renal allograft. Lancet 1980;1:1355-6.
93. Nagington J, Gray J. Cyclosporin A immunosuppression, Epstein-Barr virus antibody, and lymphoma. Lancet 1980;1:536-7.
94. Larson RS, Scott MA, McCurley TL, Vnencak-Jones CL. Microsatellite analysis of posttransplant lymphoproliferative disorders: Determination of donor/recipient origin and identification of a putative lymphomagenic mechanism. Cancer Res 1996;56:4378-81.
95. Edwards RH, Raab-Traub N. Alterations of the p53 gene in Epstein-Barr virus-associated immunodeficiency-related lymphomas. J Virol 1994;73:1309-15.
96. Birx DL, Redfield RR, Tosato G. Defective regulation of Epstein-Barr virus infection in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related disorders. N Engl J Med 1986;314:874-9.
97. Knowles DM, Inghirami G, Ubraico A, et al. Molecular genetic analysis of three AIDS-associated neoplasms of uncertain linearge demonstrates their B cell derivation and the possible pathogenetic role of Epstein-Barr virus. Blood 1989;73:792-9.
98. Pelicci PG, Knowles DM, Arlin Z, et al. Multiple monoclonal B cell expansion and c-myc oncogene rearrangement in AIDS-related lymphoproliferative disorders: Implications of lymphomagenesis. J Exp Med 1986;164:2049-60.
99. Petersen JM, Tubbs RR, Savage RA, et al. Small non-cleaved B cell Burkitt-like lymphoma with chromosome t(8;14) translocation and Epstein-Barr virus nuclear-associated antigen in a homosexual man with acquired immune deficiency syndrome. Am J Med 1985;78:141-8.
100. Chaganti RSK, Jhamwar SC, Koziner B, et al. Specific translocations characterize Burkitt's-like lymphoma of homosexual men with the acquired immunodeficiency syndrome. Blood 1983;61:1269-72.
101. Alonso ML, Richardson ME, Metroka CE, et al. Chromosome abnormalities in AIDS-associated lymphadenopathy. Blood 1987;69:855-8.
102. Geddes JF, Bhattacharjee MB: Savage K, Scaravelli F, McLaughlin JE. Primary cerebral lymphoma: a study of 47 cases probed for the Epstein-Barr virus genome. J Clin Pathol 1992;45:587-90.
103. Murphy JK, Young LS, Bevan IS, et al. Demonstration of Epstein-Barr virus in primary brain lymphoma by in situ DNA hybridisation in paraffin wax embedded tissue. J Clin Pathol 1990;43:220-3.
104. Kolter SP, Riggs SA, Cabanillas F, et al. Aggressive non-Hodgkin's lymphomas in immunocompromised homosexual males. Blood 1985;66:655-9.
105. Sauvageau G, Stocco R, Kasparian S, Menezes J. Epstein-Barr virus receptor expression on human CD8 + T lymphocytes. J Gen Virol 1990;71:379-86.
106. Hedrick JA, Watry D, Speiser C, et al. Interaction beween Eptein-Barr virus and a T cell line (HSB-2) via a receptor phenotypically distinct from complement receptor type 2. Eur J Immunol 1992;22:1123-31.
107. Kikuta H, Taguchi Y, Tomizawa K, et al. Epstein-Barr virus genome-positive T lymphocytes in a boy with chronic active EBV infection associated with Kawasaki-like disease. Nature 1988;333:455-7.
108. Ho FCS, Srivastava G, Loke SL, et al. Presence of Epstein-Barr virus DNA in nasal lymphomas of B and T cell type. Hematol Oncol 1990;8:271-81.
109. Tsang WYW, Chan JKC, Yip TT, et al. In situ localization of Epstein-Barr virus encoded RNA in non-nasal/nasopharyngeal CD56-positive and CD56-negative T-cell lymhphomas. Hum Pathol 1994;25:758-65.
110. Ho FCS, Choy D, Loke SL. Polymorphic reticulosis and conventional lymphomas of the nose and upper aerodigestive tract: a clinicopathologic study of 70 cases, and immunophenotypic studies of 16 cases. Hum Pathol 1990;21:1041-50.
111. Wong KF, Chan JKC, Ng CS, et al. CD56(NKH1)-positive hematolymphoid malignancies: an aggressive neoplasm featuring frequent cutaneous/mucosal involvement, cytoplasmic azurophilic granules and angiocentricity. Hum Pathol 1992;23:798-804.
112. Chen HW, Fan LL, Su IJ, et al. Experience of radiotherapy in midline lethal lesion with special emphasis on T cell lymphoma. Radiother Oncol. 1996;38:1-6.
113. Hsiao CH, Lee WY, Chang SJ, Su IJ. Angiocentric T cell lymphoma of the intestine: a distinct etiology of ischemic bowel disease. Gastroenterology 1996;110:985-90.
114. Tsai TF, Su IJ, Lu YC, et al. Cutaneious angiocentric T-cell lymphoma associated with Epstein-Barr virus. J Am Acad Dermatol 1992;26:31-8.
115. Jaffe ES, Chan JK, Su IJ, et al. Angiocentric nasal and extranasal T/NK cell lymphoma: Summary of a workshop on clinical features, definition, and prognosis. Am J Surg Pathol 1996;20:103-11.
116. Weiss LM, Picker LJ, Grogan TM, Warnke RA, Sklar J. Absence of clonal beta and gamma T-cell receptor gene rear-rangements in a subset of peripheral T-cell lymphomas. Am J Pathol 1988;130:436-42.
117. Su IJ, Lin KH, Chen CJ, et al. Epstein-Barr virus-associated peripheral T-cell lymphoma of activated CD8 phenotype. Cancer 1990;66:2557-62.
118. Anagnostopoulos I, Hummel M, Finn T, et al. Heterogeneous Epstein-Barr virus infection patterns in peripheral T-cell lymphoma of angioimmunoblastic lymphadenopathy type. Blood 1992;80:1804-12.
119. Knecht H, Sahli R, Shaw P, et al. Detection of epstein-Barr virus DNA by polymerase chain reaction in lymph node biopsies from patients with angioimmunoblastic lymphadenopathy. Br J Hematol 1990;75:610-4.
120. Anagnostopoulos I, Herbst H, Niedobitek G, Stein H. Demonstration of monoclonal EBV genomes in Hodgkins disease and Ki-1-positive anaplastic large cell lymphoma by combined Southern blot and in situ hybridisation. Blood 1989;74:810-6.
121. Kanavaros P, Jiwa NM, de Bruin PC, et al. High incidence of eBV genome in CD30-positive non-Hodgkin's lymphomas. J Pathol 1992;168:307-15.
122. Su IJ, Hsu YH, Liu MT, et al. Epstein-Varr virus-containing T-cell lymphoma presents with hemophagocytic syndrome mimicking malignant histiocytosis. Cancer 1993;72:2019-27.
123. Yao M, Cheng AL, Su IJ, et al. Clinicopathological spectrum of haemophagocytic syndrome in Epstein-Barr virus-associated peripheral T-cell lymphoma. Br J Haematol 1994;87:535-43.
124. Ishii E, Ohga S, Aoki T, et al. Prognosis of children with virus-associated hemophagocytic syndrome and malignant histiocytosis: correlation with levels of serum interlekin-1 and tumor necrosis factor. Acta Hematol 1991;85:93-9.
125. Yoneda T, Alsina MA, Chavez JB, et al. Evidence that tumor necrosis factor plays a pathogenetic role in the paraneoplastic syndromes of cachexia, hypercalcemia, and leukocytosis in a human tumor in nude mice. J Clin Invest 1991;87:977-85.
126. Heise MT, Vigin HW. The T-cell-independent role of gamma interferon and tumor necrosis factor alpha in macrophage activation during murine cytomegalovirus and herpes simplex virus infections. J Virol 1992;69:904-9.
127. Herbst H, Niedobitek G, Kneba M, et al. High incidence of Epstein-Barr virus genomes in Hodgkin's Disease. Am J Pathol 1990;137:13-8.
128. Herbst H, Dallenbach F, Hummel M, et al. Epstein-Barr virus latent membrane protein expression in Hodgkin and Red-Sternberg cells. Proc Natl Acad Sci USA 1991;88:4766-70.
129. Anagnostopoulos I, Hummel M. Epstein-Barr virus in tumors. Histopathology 1996;29:297-315.
130. Shibata D, Hansmann ML, Weiss LM, Nathwani BN. Epstein-Barr virus infections and Hodgkin's disease: A study of fixed tissues using the polymerase chain reaction. Hum Pathol 1991;22:1262-7.
131. Knecht H, Odermatt BF, Bachmann E, et al. Frequent detection of Epstein-Barr virus DNA by the polymerase chain reaction in lymph node biopsies from patients with Hodgkin's disease without genomic evidence of B or T cell clonality. Blood 1991;78:760-7.
132. Weinreb M, Day PRJ, Murray PG, et al. Epstein-Barr virus (EBV) and Hodgkin's disease in children: incidence of EBV latent membrane protein in malignant cells. J Pathol 1992;168:365-9.
133. Jarrett RF, Gallagher A, Jones DB, et al. Detection of Epstein-Barr virus genomes in Hodgkin's desease: relation to age. J Clin Pathol 1991;44:844-8.
134. Vestlev PM, Pallesen G, Sandvej K, Hamilton-Dutoit SJ, Bendtzen SM. Prognosis of Hodgkin's Disease is not influenced by Epstein-Barr virus latent membrane protein. Int J Cancer 1992;50:670-1.
135. Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS. Expression of Epstein-Barr virus latent gene products in tumor cells of Hodgkin's disease. Lancet 1991;337:320-2.
136. Hammerschmidt W, Sugden B, Baichwal VR. The transforming domain of the latent membrane protein of the Epstein-Barr virus is toxic to cells when expressed at high levels. J Virol 1989;63:2469-75.
137. Frisan T, Sjöberg J, Dolcetti R, et al. Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood 1995;86:1493-502.
138. Abdel-Hamid M, Chen JJ, Constantine N, Massoud M, Raab-Traub N. EBV strain variation: Geographical distribution and relation to disease state. Virology 1992;190:168-75.
139. Borisch B, Finke J, Henning I, et al. Distribution and localization of Epstein-Barr virus subtypes A and B in AIDS related lymphomas and lymphatic tissue of HIV positive patients. J Pathol 1992;168:229-33.
140. Borisch B, Henning I, Lawng RH, et al. Association of the subtype 2 of Epstein Barr virus with T cell non-Hodgkin's lymphoma of the midline granuloma type. Blood 1993;82:858-64.
141. Boyle MJ, Sewell WA, Seulley TB, et al. Subtype of Epstein-Barr virus in human immunodeficiency virus-associated non-Hodgkin lymphoma. Blood 1991;78:3004-11.
142. Miyashita T, Kawaguchi H, Asada M, et al. Epstein-Barr virus type B in patients with T-cell lymphoma. Lancet 1991;337:1045-6.
143. Sample J, Kieff EF, Kieff ED. Epstein-Barr virus type 1 and type 2 have nearly identical LMP-1 transforming genes. J Gen Virol 1994;75:2741-6.
144. Whang-Peng J, Knutsen T, Jaffe ES, et al. Sequential analysis of 43 patients with non-Hodgkin's lymphoma:clinical correlation with cytogenetic, histologic, immunophenotypic, and molecular studies. Blood 1995;85:203-16.
145. Thangavelu M, Snyder L, Anastasi J. Cytogenetic chracterization of B-cell lymphomas from severe combined immunodeficiency disease mice given injections of lymphocytes from Epstein-Barr virus-positive donors. Cancer Res. 1992;52:4678-81.
146. Tien HF, Su IJ, Chuang SM, et al. Cytogenetic characterization of Epstein-Barr virus-associated T cell malignancy. Cancer Genetics cytogenet 1993;69:25-30.
147. d'Amore F, Johansen P, Houmand A, et al. Epstein-Barr virus genome in non-Hodgkin's lymphomas occurring in immunocompetent patients: Highest prevalence in nonlymphoblastic T-cell lymphoma and correlation with a poor prognosis. Blood 1996;87:1045-55.
148. Cheng AL, Su IJ, Chen YC, Lee TC, Wang CH. Expression of p-glycoprotein and glutathione-S-transferase in recurrent lymphomas: The possible role of Epstein-Barr virus, immunophenotypes, and other predisposing factors. J Clin Oncol 1993;11:109-15.